UK-based pharma Indivior has agreed a takeover deal with Opiant Pharma that consolidates its position in the addiction treatment category with a new intranasal therapy, due to be filed with
Indivior has failed in its bid to prevent a lawsuit claiming that it illegally blocked competition to opioid addiction drug Suboxone from coming to court in the US.
Indivior has paid out $300 million to resolve civil claims from US states after it was last year found guilty against criminal charges of improper marketing of the opioid addiction drug Sub
UK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in the US behind it, after agreeing a $600 million settlement.
The resignation of Indivior chief executive Shaun Thaxter this week was swiftly followed by a guilty plea – and possible prison sentence – after he pleaded guilty in a US feder
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho